ValuentumAd

Official PayPal Seal
Valuentum Reports













Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Latest Valuentum Commentary

Mar 20, 2015
Hooray! Biogen’s Breakthrough Alzheimer’s Drug?
Biogen’s potential new drug could help millions of people suffering from Alzheimer’s.
Feb 5, 2015
Some Wiggle Room, Please
Lots of earnings reports out. Let’s go around the horn.
Jan 5, 2015
4 Opportunistic Stocks To Consider Buying in 2015
The Valuentum Buying Index has registered a high rating in the past on these four investment ideas. 2015 may mark strong gains for these gems.
Dec 22, 2014
Dividend Increases for the Week Ending December 19
Let's take a look at dividend increases for the week ending December 19.
Aug 26, 2014
Price Is Almost Always Different Than Value
This key tenet behind stock market investing success is worth remembering.
Jul 30, 2014
Big Pharma Round Up
Let’s take a look at recent quarterly results from Big Pharma.
Jun 22, 2014
Valuentum Economic Castle™ Rating Update
Members should expect the initial Economic Castle™ ratings.
Jun 17, 2014
Firms Leaving United States for More Reasonable Tax Rates Elsewhere
Medtronic is the latest firm to pursue tax inversion via its tie-up with Covidien. Importantly, however, the firm renewed its commitment to dividend growth shareholders, hiking the payout 9%.
May 19, 2014
Merger Mania: AT&T Ties the Knot with DirecTV; Pfizer Ups Offer for AstraZeneca; Siemens Complicates Matters for GE
M&A activity continues to be robust across most sectors. Let’s take a look at three deals that continue to dominate headlines.
May 3, 2014
Teva Pharma: Underpriced and Misunderstood
The generics pharma giant remains one of our top ideas.


Latest News and Media
The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.